Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms (Q40874901)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms |
scientific article |
Statements
1 reference
Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms (English)
1 reference
Harjunpää A
1 reference
Junnikkala S
1 reference
Meri S
1 reference
1 June 2000
1 reference
1 reference
Identifiers
1 reference